Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
DAHHAN v. OvaScience, Inc. et al
Case Number:
1:17-cv-10511
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
June 22, 2022
Robbins Geller Seeks Third Of $15M OvaScience Settlement
Robbins Geller Rudman & Dowd LLP asked Tuesday for a one-third cut of a $15 million settlement that investors won from OvaScience and its venture capital backer Longwood Fund over shareholder losses allegedly caused by misrepresentations about the success of a new fertility treatment.
-
March 07, 2022
OvaScience, VC Fund Settle Investor Class Action For $15M
OvaScience and its venture capital backer Longwood Fund have agreed to pay $15 million to resolve an investor class action saying the Massachusetts fertility company's alleged misrepresentations about the success of a new treatment eventually led to shareholder losses.
-
May 28, 2021
Venture Firm Can't Escape OvaScience IVF Suit, Judge Says
A Massachusetts federal judge said Friday securities fraud claims against a venture capital firm that was "running the show" at a fertility treatment company could go forward, rejecting arguments that the claims were late-raised by lead plaintiffs in the investor class action.
-
May 08, 2020
Robbins Geller Must Add Atty Names To Lead OvaScience Suit
Robbins Geller Rudman & Dowd LLP must specify which attorneys will lead a suit by OvaScience investors who claim the company inflated the success of its in vitro fertilization treatment, a judge said Friday, but otherwise ruled the case fits the bill for class certification.
-
March 15, 2019
OvaScience Investor Seeks Cert. In IVF Treatment Suit
An OvaScience investor asked a Massachusetts federal judge on Thursday to certify a class in a suit accusing the fertility company of inflating the success of its in vitro fertilization treatment, saying its securities claims are a perfect fit for class treatment.
-
July 31, 2018
OvaScience Can't Escape Investor IVF Treatment Suit
A Massachusetts federal judge has refused to toss a shareholder suit alleging OvaScience Inc. misrepresented the success of its in vitro fertilization treatment, saying Tuesday she was unconvinced by the company's rebuttals to investors' allegations that certain company statements were misleading.
-
July 16, 2018
OvaScience Investors Cannot Overtake Rival Class Action
A Massachusetts federal judge on Monday refused to let one securities class action against OvaScience Inc. take over a similar but separate class action, denying an argument that overlapping class periods could confuse investors and threaten each other's cases.
-
November 13, 2017
OvaScience Can't Duck IVF Treatment Suit, Shareholders Say
Shareholders suing OvaScience Inc. for allegedly misrepresenting the success of its fertility treatment have urged a Massachusetts federal court to keep their proposed class action alive, saying they have sufficiently detailed their claims.